Darolutamide plus androgen deprivation therapy (ADT), without docetaxel, significantly prolonged radiographic progression-free survival compared with placebo plus ADT in patients with metastatic ...

Darolutamide (Nubeqa) combined with standard treatment significantly improved survival in patients with metastatic hormone-sensitive prostate cancer (mHSPC), the phase III ARASENS trial found. At data ...

SAN FRANCISCO — Treatment with the investigational agent darolutamide (Bayer/Orion) significantly extended metastasis-free survival in patients with nonmetastatic castration-resistant prostate cancer ...

MINNEAPOLIS, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it has entered ...

Darolutamide (Nubeqa) was linked with a decrease in locally invasive procedures, as well as local urinary and bowel symptoms, in patients with nonmetastatic (nm) castration-resistant prostate cancer ...

Adding darolutamide to ADT and docetaxel improves overall survival in patients with metastatic hormone-sensitive prostate cancer. Adding darolutamide to androgen deprivation therapy (ADT) and ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved darolutamide tablets in combination with docetaxel for men with metastatic hormone-sensitive ...

CHMP adopts positive opinion for the marketing authorisation of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer ...

European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC). Approval is based on ...